Adverum Biotechnologies Announces Virtual Presentations of Data through ASGCT and ARVO
Adverum Biotechnologies, Inc. (ADVM)
Last adverum biotechnologies, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adverum.gcs-web.com/investor-overview
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced several virtual presentations of data from the company’s gene therapy programs in May 2020. American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting 2020Abstracts are available online and presentations and posters can be accessed through ASGCT’s website on May 12, 2020 at www.asgct.org. Abstract Title (Oral): ADVM-022 Intravitreal Gene Therapy for Neovascular AMD - Results from the Phase 1 OPTIC Study Session: AAV Vectors - Clinical Studies IIDate/Time: Wednesday, May 13, 2020, 4:00 - 4:15 pm EDTSpeaker: Szilárd Kiss, M.D., Director of Clinical Research in the Department of Ophthalmology at Weill Cornell Medical Group Abstract Title (Poster): Proof-of-Concept Studies in Mongolian Gerbils Support Intravitreal Gene Replacement Therapy of Human L-Op
Show less
Read more
Impact Snapshot
Event Time:
ADVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADVM alerts
High impacting Adverum Biotechnologies, Inc. news events
Weekly update
A roundup of the hottest topics
ADVM
News
- Adverum Reminds Stockholders to Tender their Shares into the Offer by LillyGlobeNewswire
- Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
- $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOUS, ADVM, HBAN, and COMPPR Newswire
- Adverum Biotechnologies (NASDAQ:ADVM) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, down previously from $30.00.MarketBeat
- Shinobi Therapeutics Announces the Appointment of Dr. Laurent Fischer as Chair of its Board of Directors [Yahoo! Finance]Yahoo! Finance
ADVM
Earnings
- 11/12/25 - Miss
ADVM
Sec Filings
- 12/4/25 - Form 8-K
- 12/3/25 - Form 4
- 12/1/25 - Form SC
- ADVM's page on the SEC website